logotype
  • Home
  • About Us
  • Events
    • Upcoming Conferences
    • Past Conferences
  • Event Support
  • Careers
  • Contact Us
logotype
  • Home
  • About Us
  • Events
    • Upcoming Conferences
    • Past Conferences
  • Event Support
  • Careers
  • Contact Us
  • Home
  • About Us
  • Events
    • Upcoming Conferences
    • Past Conferences
  • Event Support
  • Careers
  • Contact Us
logotype
logotype
  • Home
  • About Us
  • Events
    • Upcoming Conferences
    • Past Conferences
  • Event Support
  • Careers
  • Contact Us
February 8, 2024

Bora Pharmaceuticals To Acquire Upsher-Smith For $210mn

by info@virtueinsight.comNews0 Comments

 

 

Bora Pharmaceuticals, a contract development and manufacturing organization (CDMO), has officially acquired Upsher-Smith Laboratories, a specialty-brand and generics company, for $210 million.

Upsher-Smith, founded in 1919 and owned by Sawai since 2017, has a diversified portfolio of 48 generic products with manufacturing facilities in Plymouth and Maple Grove, Minnesota. Upsher-Smith is highly respected in the industry and is recognized as a reliable partner with solid manufacturing capabilities, a robust distribution network, and established commercial relationships. Upsher-Smith’s product portfolio also presents significant opportunities for Bora’s commercial Rx business, TWi, in the US. Upsher-Smith’s decades-long presence in the US generics market offers deep industry expertise and know-how, as well as a well-recognized and respected name.

Founded in 2007, Bora Pharmaceutical, now is the largest pharmaceutical manufacturer in Taiwan with well-connected global distribution to supply more than 100 countries around the world. Headquartered in Taiwan, Bora has dedicated itself to become a global leader in pharmaceutical manufacturing by offering its clients with best quality, efficiency and reliability.

Bobby Sheng, Chairman and CEO of Bora Group, said, “This is a significant milestone for Bora Group, marking the most critical expansion of Bora’s presence in the US market and significantly enhancing Bora’s position as a global competitor with regard to its CDMO business and commercial Rx business.”

“Upsher-Smith’s competitiveness is a perfect match to Bora’s long-term growth – its newly-expanded, USFDA-approved manufacturing facilities, with a total capacity of 3.5 billion doses, will be Bora’s first local facility in the US, establishing a crucial stronghold for our global CDMO business.”

The closing of the transaction is subject to customary regulatory approvals. Upon closing, Bora, via its wholly-owned subsidiary in the US, will acquire 100% equity interest of Upsher-Smith.

Visit our upcoming pharma conferences – https://virtueinsight.com/upcoming-conferences/

anticounterfeiting biosimilars biotech biotechnology clinicaltrials Counterfeit healthcare pharma pharmaceutical pharmacovigilance pharmaindustry pharmareglatory serialazation supplychain

 

 

Bora Pharmaceuticals, a contract development and manufacturing organization (CDMO), has officially acquired Upsher-Smith Laboratories, a specialty-brand and generics company, for $210 million.

Upsher-Smith, founded in 1919 and owned by Sawai since 2017, has a diversified portfolio of 48 generic products with manufacturing facilities in Plymouth and Maple Grove, Minnesota. Upsher-Smith is highly respected in the industry and is recognized as a reliable partner with solid manufacturing capabilities, a robust distribution network, and established commercial relationships. Upsher-Smith’s product portfolio also presents significant opportunities for Bora’s commercial Rx business, TWi, in the US. Upsher-Smith’s decades-long presence in the US generics market offers deep industry expertise and know-how, as well as a well-recognized and respected name.

Founded in 2007, Bora Pharmaceutical, now is the largest pharmaceutical manufacturer in Taiwan with well-connected global distribution to supply more than 100 countries around the world. Headquartered in Taiwan, Bora has dedicated itself to become a global leader in pharmaceutical manufacturing by offering its clients with best quality, efficiency and reliability.

Bobby Sheng, Chairman and CEO of Bora Group, said, “This is a significant milestone for Bora Group, marking the most critical expansion of Bora’s presence in the US market and significantly enhancing Bora’s position as a global competitor with regard to its CDMO business and commercial Rx business.”

“Upsher-Smith’s competitiveness is a perfect match to Bora’s long-term growth – its newly-expanded, USFDA-approved manufacturing facilities, with a total capacity of 3.5 billion doses, will be Bora’s first local facility in the US, establishing a crucial stronghold for our global CDMO business.”

The closing of the transaction is subject to customary regulatory approvals. Upon closing, Bora, via its wholly-owned subsidiary in the US, will acquire 100% equity interest of Upsher-Smith.

Visit our upcoming pharma conferences – https://virtueinsight.com/upcoming-conferences/

prev

GSK acquires Aiolos Bio for $1.4bn to boost respiratory portfolio

next

Sanofi to buy biotech firm Inhibrx in $2.2bn deal to boost rare disease business

RELATED POSTS

June 5, 2023
News

EyePoint to sell YUTIQ to Alimera Sciences

read more
October 5, 2023
News

Valo Health bags $2.7bn AI partnership with Novo Nordisk

read more

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

logotype

We strive to produce high quality conferences which include the latest topics which are delivered by world class leaders of the industry.

Facebook-fTwitterYoutubeLinkedin-inInstagramPinterest

Quick Links

About us
Contact us
Event Support
Careers
Privacy Policy
Terms & Conditions

Subscribe to our newsletter

    © 2025 Virtue Insight. All rights reserved.